Yes, the title of this article is misleading, dangerous crap. Sorry, but I just took it directly from the ad — the ad I’m writing about today is from Patrick Cox for his Breakthrough Technology Alert, a relatively expensive ($895) newsletter that focuses on, well, breakthrough technologies, mostly stocks that we’d classify as biotechs or leading edge tech stocks, and almost all very small companies. I had a short list of several interesting teasers to focus on for you this morning, and the fact that this is being pitched as “The Last Stock You’ll Ever Need” pushed me over the edge.
So which is this last stock that you’ll ever need to buy? The ad is a very similar pitch to what Patric Cox has used before — his ads almost always talk about being in on the ground floor of universe-shaking ideas, of building generational wealth through incredible breakthroughs. Nothing boring in here about solid balance sheets, dividends, diversification, or even patience — though of course, most of the stocks he writes about are far from becoming large and profitable enterprises.
This is the most tempting kind of stock pitch: that there’s an idea so good that it can change the way you live, so good, indeed, that it can change the way your grandchildren live as you build a generation-spanning cache of lucre. The most prominent pitches from him in recent years have been for stem cell stocks like Geron (GERN) and BioTime (BTX) or early-stage biotech stocks fighting cancer or alzheimer’s, and occasionally for cutting edge stocks in other areas, like Lightbridge (LTBR) for their thorium reactor technology or NVE Corp (NVEC) for their spintronics patents. The same stocks tend to repeat themselves from time to time in his pitches, so a few of those (and maybe also today’s, we’ll find out soon) were also pitched in his ad a couple months back that promised a revolution whose impact would rival that of the printing press.
Today? We’re told, of course, that it might be the last stock you’ll ever want to buy — so who is it?
I’m not going to do a lot of direct quoting, since Cox doesn’t make the transcript of his “video” presentation available, but I’ll give you the gist. Here, at least, is the bold type intro:
“Only a Handful of Researchers and Experts In the Entire World Know What You’re About to See…
“The LAST STOCK You’ll Ever Need
“You’re about to witness a shocking, hidden story.
“This could also be the biggest market story in history.
“You must act on this urgent wealth creation event before Midnight, Monday, May 30th.”
The urgency of May 30 is not that there’s necessarily going to be any news out of this company … it’s that they’ll be taking down the ad presentation. Which will be a horrific loss to all of us, I’m sure.
But Cox does indicate that there are good things ahead in the near future for this company — partly because of his sunny interpretation of their actual work, and partly because of insider buying, which provides our first clue.
He says that the CEO recently bought 500,000 shares with his own money and now owns about 9% of the shares, and that insiders overall own about 30% … which does sound promising.
And he names an impressive list of institutional investors who also own the shares, like Goldman Capital, BlackRock, and Vanguard … though of course all good little Gumshoes know that finding a decent-sized stock without an impressive list of institutional investors is almost impossible. So that’s another hint, though not a particularly exciting factoid.
We get more hints as well — including that researchers at a “famous institute in Florida” and at Johns Hopkins University are “absolutely floored” by the breakthrough potential of this company … potential that Cox applies most urgently to Alzheimer’s Disease but that he says could also be a “supertreatment” for a baker’s dozen of big diseases and nasty conditions, including cancer, macular degeneration, stroke, obesity, erectile dysfunction, allergies, Crohn’s Disease, rheumatoid arthritis … well, you name it.
Why? Because he describes this company’s breakthrough as a potentially life-changing treatment that gets at the core problem behind many of these diseases: inflammation. He says that the “supertreatment” fights this core cause of pain and disease, and that it is derived from, among other things, tomatoes and red peppers.
So what’s the stock?
Well, if you decide this is the “last stock you’ll ever need” and throw all your money into it, please don’t come crying to me if that turns out to be entirely wrong, but this is …
Star Scientific (CIGX)
This is a company I’ve briefly mentioned in other articles on Patrick Cox teaser picks and he seems to have liked it for at least a few months now, which has helped the stock get some attention … though the far bigger news has been their ongoing patent litigation with the big tobacco companies, which was the spur behind much of the stock’s move earlier this year. It’s also a stock that I hold some call options on, so do keep in mind that I have a conflict on these particular shares (though now that I’m writing about it, I can’t trade in the stock or options for at least three days).
And yes, it’s a pretty small company — market cap now about $500 million, so not infinitesimally small like some Cox picks, but certainly small enough to move based on discussion board posts, minor news items, or even the comments of yours truly. Volume has certainly been quite high ever since the stock doubled following their latest good news from the courtroom in early March, so the stock is very liquid (ie, plenty of buyers and sellers) compared to some little biotech-y stocks that I write about.
There are basically two core businesses at Star Scientific — one is making healthier tobacco through their patented curing process that helps to reduce or eliminate toxins; and the other is, for lack of a better term, nutraceutical research. The first part is what moved the stock earlier this year, when a judge upheld Star’s patent on that curing process in a long-running dispute with Reynolds; and the second part goosed that a little bit when the FDA ruled that new versions of some of their “modified risk tobacco products” (basically, “hard snuff” lozenges with fewer carcinogens — the products are called Stonewall and Ariva) didn’t require FDA approval as tobacco products, but neither of those really gets at the heart of Patrick Cox’s pitch for the company.
"reveal" emails? If not,
just click here...
The real potential is that the alkaloid they’re isolating and producing from tobaco leaves, anatabine, will be a “supertreatment” for all kinds of inflammation, with the most exciting and lucrative one probably being Alzheimer’s at this point (since Alzheimer’s is probably the largest and most costly disease on earth that doesn’t have anything like an effective cure — it’s enough to give biotech investors paroxysms of greed, but the search for an Alzheimer’s cure has also brought down plenty of hope-filled biotech stocks and stymied pretty much every big pharma company at one point or another). And yes, anatabine is also present in tomatoes and peppers, though apparently it’s a huge ingredient in tobacco leaves so that’s a natural source.
Star Scientific’s pharmaceutical/nutraceutical arm, Rock Creek Pharmaceuticals, recently introduced a smoking cessation pill called CigRX that sounds like it’s basically made of anatabine — the theory being, I guess, that anatabine will help quell the nicotine cravings since both are present in tobacco and the anatabine is not considered addictive. They’re selling it directly online now, and presumably through other outlets as well, and I have no idea if or how it works. Beyond that, the hope is more exciting but also more ephemeral — Cox’s argument for near-term news seems to revolve around the fact that anatabine might get some attention as the next can’t-miss nutraceutical, and then everyone will start taking it and the demand will go through the roof. The stuff itself isn’t patented, just like you can’t patent vitamin C or nicotine, but they have filed a patent for an isolated anatabine isomer. No, I don’t really know what that means.
The potential is out there in “big picture news” and has inspired some excitement among researchers — the institute he refers to in Florida is the Roskamp Institute, and they’re doing a study now (or at least planning one — not sure on the timing) on anatabine that seems to be pointed at general inflammation and C-reactive protein. The compound’s name, in case you’re reading up, is now RCP-006. Roskamp’s focus is largely on Alzheimer’s Disease, and they’ve previously indicated that they’re beginning clinical trials in Alzheimer’s using RCP-006, but that more specific study seems to still be in the planning stage, according to the latest quarterly report.
And yes, the big dog at Star Scientific, and the man credited with discovering the tobacco curing technology or process that has been the core of the company, is CEO Jonnie Williams, and he did indeed buy about 500,000 more shares in early March, just about a week before they got the good legal news on patents. The price has more than doubled since then, and he does indeed own roughly 9% of the company (just under 12 million shares). The Tradewinds Master Fund is the largest single owner, they’re some kind of hedge fund operation and they own about 16 million shares — they say they’ve been buying for years and are invested for the long term based on the eventual potential greatness … and like Jonnie, they also bought the week before the patent decision (both buys were apparently part of a fundraising effort, they didn’t just buy on the open market).
I have no idea whether CIGX will really change the world — but I sure as heck wouldn’t call it the last stock I’m going to need, and my speculation in the shares through some options holdings is just that, a speculation in a stock that is very aggressively driven by news. If news is good, I might do very well, if news is weak or there is no news, I’ll probably lose my investment. Which is why it’s far less than 1% of my portfolio and I’m speculating with call options to strictly limit the amount of capital I have at risk … so if this turns out to be the biggest medical story ever, I’m probably going to miss my chance to create generational wealth. Dang.
Oh, and if it turns out to be just a story of blue sky potential that doesn’t pan out in the clinic or the marketplace? Well, I won’t have lost any sleep.
And just to finish up — yes the financials are terrible, and I have no reason to suspect that there will be any company news of substance before the date of May 30 that Cox throws out as the deadline (earnings came out about ten days ago). This one is really all about the “story,” whether you think the story is the potential for huge licensing fees from the tobacco companies (that was what caught my attention a while back), a revolutionary move toward healthier tobacco-derived smoking and snuff products, or a potential breakthrough someday for Alzheimer’s or inflammatory diseases and conditions.
They had less than a million dollars in revenue last year and posted losses of over $20 million, which is not the kind of company you’d want to buy for half a billion dollars unless you think the story is really, really exciting (as Cox certainly seems to) … and their most prominent current product, CigRX, which generated a substantial amount of those revenues and is in some kind of broader test marketing rollout, generated just $46,020 in the quarter. That’s thousand, I’m not leaving out any zeroes — Yahoo Finance tells us that the company currently trades for 662X sales … so no one is buying them for the present, this is all about the future.
Got a thought or a feeling on CIGX? I’m sure we’d all be delighted to hear it, just chime in using the friendly little comment box below.
P.S. I know you’re not asking, but just in case you didn’t read the whole article above and skipped straight to the P.S. … no, I do NOT think this is the “last stock you’ll ever need.” I don’t give financial advice and I’m not making recommendations here anyway, but if you’re tempted to sell your car and a kidney to buy CIGX shares, please slow down. And if you ever decide to bet your entire portfolio on a single story like this, please do not home school your children. A fun or speculative wager is one thing, going “all in” is another thing entirely.
Glutathione is huge at reducing inflamation but you can't take a glutathione pill. It is destroyed in the stomach. Here is a company that makes a product that gets your body to produce glutathione. Here is a quote from one of their products:
The Essential Glutathione
Oxidative stress has been associated with more than 74 major diseases and disorders, and defending your cells against oxidative stress is a critical function of antioxidants. One antioxidant does this job better than all the others-glutathione. It is produced naturally in the body if the required building blocks are available, and strengthens the immune system, detoxifies the body, fights intracellular inflammation, and neutralizes numerous types of free radicals. By supporting the production of glutathione, you can help your body defend itself."
go to: http://www.max.com to learn more. about glutathione and its reduction of inflamation.
While I'm not a chemist, I have worked in the drug discover industry so maybe I can fill this in a bit. I'm not going to do a lick of research on this, so everything is going to be based on assumptions that I haven't verified.
First, yes that's correct: you can't patent a natural ingredient. What you can patent are 1) the extraction process for a natural ingredient and 2) a molecule that's different from the natural one but that does the same things inside the body — or at least one hopes it does.
Implications: there are probably many ways to extract the compound and/or to make a different compound that works in the same way. If the market is gigantic, competition will be fierce. CIGX has essentially zero chance of owning that market.
Second, I would be astonished if reducing inflammation cures Alzheimer's. It might prevent it, but cure it? I doubt that because the brain has already been destroyed and you're not going to grow your brain back by reducing inflammation.
Implication: the only way to really test if this works in humans is to do clinical trials that take decades. How long do you want to wait for a product from a company that has essentially zero chance of owning the market for its product?
Last (there are more but this is enough): C-reactive protein is a well known inflammation marker. There are many pathways in the body that produce inflammation and all are under investigation because –as stated in the tease — the market potential for drugs that control inflammation is huge.
Implication: This is but one among many many many research studies that may or may not lead to an actual drug for controlling inflammation. In other words, you have about the same chances of making a profit from a drug here as you would in striking gold by digging a hole in the ground. At least if you dig in your backyard you get some exercise and can plant a tomato vine in the hole if it turns out there was no gold there. There are plenty of nice antioxidants in tomatos and they taste better on pasta than shares of CIGX.
It just took a 19% dive today, still up quite a bit over the last couple of months.
I’ve been using Anatabloc for about 8 weeks. It helps my pituitary problem and it really helps my RA. The finger joints that are demaged enough to be immobile hurt much less. The other finger joints with used to hurt but appear undamaged no longer hurt. I really like this stuff. The best part is, unlike other drugs which are fore RA, Anatabloc has no side effects.
Comment following does not directly relate to investments but may nevertheless be of interest to investors with friends or family struggling with dimensia. I recently saw a piece on utube about a helpful Alzheimer (non patentable) theory, that is that brain cells are starved for glucose and die. Like diabetes where insulin is the key to the receptors “lock” ~~ the key to the brain cells receptors “lock” is ketones. A less expensive approach than ketones , anecdotally, is PURE coconut oil added to the diet. But not hydrolyzed or hydrogenated coconut oil since those processes have health drawbacks These beneficial substances cannot be patented , so pharmaceutical companies have no interest. A Florida doctor’s husband was in bad shape and could not draw anything resembling the face of a clock before going ingesting coconut oil. His drawings over several months on the oil showed drastic improvement and his vocabulary also improved. It was theorized that this approach might also be helpful to Parkinson’s patients as well as some other categories of dimensia. Since Alzheimer’ can best be diagnosed only by autopsy, perhaps the improved patient (doctor’s husband) actually suffered some other form of dimensia.
If you want to read the full transcript from any of these type of videos it’s easy. Just close the tab on your web browser. It will ask if you want to stay on page click on “stay on page” and then you can read the whole video transcript. I do this all the time as it’s quick and easy to get through all the bla bla.
This is being pitched again as part of the “nutraceutical revolution” — latest ad starts like this:
“After this one, you might not want any other stock.
“A vice president at this company said on February 1st, ‘We believe this partnership will be a game changer for us.’
“Here’s the scoop – this tiny company just paired up with the largest retailer in its industry. Imagine getting a new cereal in every grocery store in America. That’s the size of this amazing leap forward.”
The pitch this time is that getting Anatabloc into GNC stores and the GNC website will be huge. I do see that the product is at GNC, though I wouldn’t have been able to find it if I wasn’t looking for it specifically. So yes, Virginia, Cox has not given up on these guys. They also just started a new clinical trial of their Anatabine supplement, looks like any word from this or from their existing trials with the Roskamp Institute won’t come before Summer.
I still personally hold some call options on the stock, just in case it really takes off again one of these days.
I am glad I decided to Google Patrick Cox and The Last Stock You’ll ever Need….I guess anytime someone is telling you to jump on an opportunity like this befiore a deadline/date and then is asking you for $ 895.00 you have to be a little wary……so I decided to Google these details and it brought me to your site….I’m glad it did….you’re information and insight were refreshing….I also learned the name of the company…and that was free…..I may invest a few dollars just in case you are wrong….but I think I may agree with you.
Cox is pushing the right buttons judging by the number of comments and the press claims that any emerging science is especially important in light of statistics from the Alzheimer’s Association that say the number of Americans 65 and older who have the disease is likely to increase from more than 5 million today to 13 million 40 years from now as large numbers of boomers age. Economic costs are expected to rise from $183 billion this year to more than $1 trillion by 2050. As part of the National Alzheimer’s Project Act, the government recently announced a goal of finding a way to prevent and treat Alzheimer’s disease by 2025. President Obama signed the law January 2011 and a final draft of a multi-agency plan is due to the Department of Health and Human Services in the spring.
This is both a lot attention and money (I especially like the money) . I would expect this to bring out many new claims. My personal favorite is a recent discovery (http://onlinelibrary.wiley.com/doi/10.1002/ana.22052/abstract) that will turn what has been thought for a 100 years to be the problem inside out. It is now thought that the plaque is actually a defensive reaction to the real problem of oligomers. It is thought that as the body ages, too many of these protein clumps, the oligomers, create a damaging buildup in the brain. They also may trigger the creation of tau tangles that gum up the brain’s signaling system. The plaque in the brain is like the oysters reaction to the irritating grain of sand.
Travis if you ever put this in your thinkulator and come up with a company working in this direction I hope you report on it for us all to read. You are a breath of fresh air, Thank You.
Hi Travis,
Thanks very much for your excellent service – I always read your emails with interest. You have a great writing style that is most enjoyable. I am likely going to become an Irregular in 2012.
RE: Star Scientific
Being a native of Richmond, VA, I have followed this stock pretty carefully for over the past five years, going back to when it traded under “STSI.” Like most, I was involved in STSI as a litigation play and took a small loss when they lost at trial for two yeas of infringement (nine more years of infringement still remain unresolved and the Star patents have been confirmed by priority date). And yes I have slowly accumulated a substantial position over the past year. I am well in the black but will continue to accumulate more.
I agree that the balance sheet is a mess and the price/sales multiple is outrageous, But CIGX must be evaluated like VRUS which went from $5 to $130 with almost zero sales.
I think that the StarCure patents will eventually deliver a nice licensing pay day. Despite what some people are writing, zero treble damages will be paid out to Star. The reason I am long is due to Anatabloc. The active ingrediant is actually “anatabine citrate” (scientifically known as RCP-006).
Key graph in your latest update:
“The stuff itself isn’t patented, just like you can’t patent vitamin C or nicotine, but they have filed a patent for an isolated anatabine isomer. No, I don’t really know what that means.”
You are correct, but Star has filed an international patent application for the process to produce “anatabine citrate” which is the potable form of anatabine. The “single isomer” version is going to be patented as a drug in the years to come.
Research Sepracor (recently renamed “Sunovion”) to get the basics of single isomer drugs. Take a drug cursed with side effects, split the molecule and the remaining material might become a significantly effective drug with far fewer side effects.
The irony of all the hype now associated with CIGX is that the two leaders of the company (Williams and Perito) would probably prefer that everyone stay quiet for another six months just to make sure the FDA does not get addled.
You are probably younger than me (I am 54) so I am guessing that you have not tried Anatabloc personally. I have taken it since early September for arthritis and my results have been truly amazing. I know it is not a placebo effect, as I stopped for two weeks in October and the pain returned.
Star’s January 30th press release offers the first public “hint” of what Anatabloc does for a large majority of people suffering from maladies caused by abnormal inflammation:
“Star Scientific says clinical trial shows Anatabloc lowers CRP levels in humans
Rock Creek Pharmaceuticals, a subsidiary of Star Scientific, reported initial results from Phase 2 of the RCP-006 study, which the company said shows that Anatabloc lowers C-reactive protein levels in subjects’ blood. CRP is a molecule produced by the liver in response to an inflammatory signal, and is a marker for inflammation. ”
I think the “single-isomer” preparation of anatabine citrate will eventually be the driver of a huge licensing deal with a major pharmaceutical company.
In any case, once the double-blind studies emerge proving that Anatabloc suppresses abnormal inflammation for the vast percentage of users, Star will experience incredible sales growth. The only people trying Anatabloc now are curious early adopters. If you ask 500 people on the street maybe 1 will say he knows what Anatabloc is. Now that GNC is carrying it, that will soon change.
So that is my comment and thanks again for your fair and balanced write up.
Thanks again!
check out ONCY………..
Latest tease from Patrick Cox says the breaking news now is that they’ve got a famous “brand ambassador” — that’s the endorsement by Fred Couples of anatabloc announced this week: http://www.marketwatch.com/story/pga-tour-professional-fred-couples-named-brand-ambassador-for-anatabloctm-2012-02-15
Don’t know what it will do for them, but I bet golf fans are a core demographic for ’em and certainly they’ll need a lot of marketing to get Anatabloc anywhere near the potential teased by Patrick Cox, so I suppose it makes sense.
I am in the nutraceuticals business. We had the opportunity to be in GNC stores and took a pass. The margins were awful. If this stuff really works, but does not have a patent, the Chinese will duplicate the extracts in no time flat, and the price will drop like a rock. Unless you get FDA approval, you can not say it cures or prevents Alzheimers, and the regulation is getting much worse, not better under the current FDA. Need an example? Read about Sirtris, which SGK sunk over $700M into. A patent on an extraction process? Please. The industry has been extracting compounds by a lot of different processes for a LONG TIME. Unlikely any patent will stick. Of course, Star is not afraid of litigation. Seems to be most of what they do.
In Pharmaceuticals, it’s about the product. In Nutraceuticals, it’s about the marketing.
Thanks Barry for the reminder that this will not be a cakewalk for Star. By the way, did your nutraceutical company ever have a patent, sign a US$200 million licensing deal to monetize that patent, build a business model around that licensing deal and then have a 3rd party buy your licensee and tell you to bugger off? I am guessing the answer is ‘No.” That is why Star has been in court for a decade. You suggest that Star’s case is less than honorable. That is the StarCure side of the Star story. In any case, there are already people claiming to make their own anatabine “potion”, an indicator that the anecdotal evidence is pretty strong that Anatabloc will make for nice marketing copy . If a Chinese firm does in fact try to replicate Star’s anatabine citrate preparation process, can they overcome the shady reputation their healthcare products have in the marketplace? Would you willingly ingest a copycat dietary supplement that you knew full well was a “knock-off” made in China? I did not think so. Meanwhile, Fred Couples will be showcasing his golf swing on TV with the Anatabloc logo on his left shoulder. I like Star’s chances here – and in court too.
Here I am, spending time researching something that this Pat Cox promoted 15 months ago. First of all, when I do a stock symbol search for CIGX, I get nothing….. is that the current symboll? And why has no one commented here since May of 2011, ” now” being Sept 2012?
Anything new we should know. Thanks!
Travis, I love your service, thanks.
Star Scientific and Anatabloc continue to be teased by Cox and I’ve written about them a few times since this article, but they did change tickers — it’s now STSI
The carcinogens are formed when an (any) organic compound is burned. Tobacco has numerous carcinogens but as any organic product will do when ignited, carcinogens are formed from the material itself combines with oxygen, nitrogen, and sulfur (mainly). Benzene ring analogs are all over the place, mostly carcinogenic. Very little done to tobacco prior to smoking can alter the smoke being carcinogenic. Products that claim to render something else impotent to induce cancers would be highly valuable, but we are not there yet. Smoking remains the single most important cause for preventable death.
Well, the company now has a new product named anatabloc. I can be purchased online or at GNC stores. Inflammation causes pain and Anatabloc makes that pain go away. I tried it and it works. Anyone who has cronic pain should buy this product ……
Is there any known side effect when taking this product?
GNC Testimonials
By vaq78
from Reno, NV
I saw this product on the GNC website and read the many reviews. Decided to give it a go and it has absolutely changed my life, for the better! I am 52 years old with many knee pain issues due to my decades of involvement in sports. I currently officiate many of the sports I played as a young person to include Basketball, Softball, and Volleyball. I have always been on the look out for the ‘Magic Pill’ to help ease my knee pain. I have had knee surgeries on both knees, steroid injections, and have tried all types of joint relief products to include Glucosamine/Chondroitin, in pill form and drink/liquids, etc. Not much was ever effective until I tried this product. Within the first day of taking these I could already feel a big difference. I have now taken this product for 5 months and I can honestly say this has changed my life! This is the best joint pain relief medication I have ever tried! Where I used to take multiple doses of over-the-counter pain medications, such as Alieve and IBprofen, etc., when I would workout or go work my games all day long, I now take my two little pills (which I let desolve under my tongue), three times a day and I am pretty much pain free. It has been a real blessing in my life and I am so jazzed to have discovered this product. A total thumbs up!
works better than prednisone
By pcallicoat
from bremerton,wa
I started using Cigrx and switched to Anatabloc back in January,2012.It has really helped my arthritis,sinus and general overall health.I used as many as 6 at one time when my bum knee was
acting up after hiking 6 miles while carting out a 300# mule deer last month during hunting season. I helped bring out another deer the next day,too without any knee pain or discomfort. Real deal and going to change modern medicine when the word gets out.
Well here it is Nov 27th 2012 and I just got the tease in my email. So, I guess there is still time to take advantage of an opportunity that was going to end over a year ago. /sarc
Thanks for having done the leg work. I’ll keep stacking silver, I’ll let others chase paper.
Well I guess that’s why you guys are on here bashing stuff because you actually don’t know how to make real money from stocks. That’s why I’m wealthy and you’re not. By the way a lot of the information came from Agora products. Go figure.
I came across this teaser from David Gardner that other readers might also enjoy seeing you sleuth: This Stock Could Be Like Buying Amazon in 1997
By: David Hanson
Pasted
Not to alarm you but you’re about to miss an important and rare event.
You see, renowned investor David Gardner (whose Stock Advisor newsletter was reported in The Wall Street Journal as one of the best performing in the world*) just revealed his next great stock idea.
And something very particular about David’s pick has some investors buzzing with excitement.
David issued a rare “buy” alert on a stock that just recently held its IPO and went public.
Shares of this company have only been available to the public for a few months, and David believes now is the perfect time to make a move on this stock.
Here’s why this is such an important (and rare) move:
In Stock Advisor’s 14 year history, there have been only 4 occasions David Gardner has recommended shares of company that held its IPO within 5 months of his “buy” alert.
That’s incredible! Only 4 times has David looked at a brand new stock and IMMEDIATELY believed he found a winner.
Usually, David likes to wait and see a company prove itself in the public markets for a few years before recommending investors buy shares, but sometimes, on rare occasions, he believes in a company so much, he pounds the table for investors to act fast and grab shares.
Perhaps no example better highlights this rare conviction like David’s September 1997 recommendation of Amazon.com. Amazon was a small-cap stock that had just gone public on May 15, 1997 when David Gardner first published his detailed, 4,250 word “buy” report on Amazon’s stock AND added shares to his portfolio.
David predicted Jeff Bezos’s vision for Amazon. David told investors “Amazon is about more than just books.”
Amazon had been public for just 4 months when David issued this bold “buy” recommendation but boy, did it pay to listen.
A mere two weeks after David recommended buying shares of Amazon, the stock had already surged more than 41%.
Many investors would be elated with a 41% pop and sell out. Not David.
David refused to sell — fast forward to today, Amazon’s stock is up a mind-boggling 20,000% — turning every $5,000 invested in Amazon into nearly $1 million today.
While you can’t go back in time and invest in Amazon alongside David Gardner, I believe I’m offering you the next best thing…
Which brings me back to the newly IPO’d company David recommended Friday afternoon – a company with strikingly similar traits to what made David first issue his Amazon call.
First, with a market cap of around $3.7 billion, this fresh IPO stock is essentially still a small-cap.
And like Amazon, this company has been growing like gangbusters!
The company has grown the size of its user base by 63% annually for the past 4 years – giving it more than double the market share of its next closest competitor.
Even more exciting, management still believes they’ve only captured 11% of the potential market for their product.
That’s the type of growth and market opportunity that gets David Gardner’s heart pumping.
Remember the old saying, “the early bird gets the worm” – an ageless mantra reminding us early movers often have the best chance of success.
That’s exactly why David is recommending investors buy shares now.
But please note: as of right now, you could miss out because you may not be eligible to access David’s pick.
You see, David Gardner only releases these recommendations to members of his service, Motley Fool Stock Advisor.
Lucky for you, it’s not too late to join, so I’m going to show you the simple steps to secure access today.
It’s very telling that David couldn’t wait any longer to recommended a newly IPO’d stock with these unmistakable traits.
And while I would never guarantee David’s newest recommendation will produce Amazon-like returns, this stock is already up over 25% since David recommended it a few weeks ago.
Even though timing isn’t everything, history shows that it can pay to move early on stocks like this one — especially when you consider David’s average pick in Stock Advisor is up 174%! (And yes, that includes all his winners and losers!)
Don’t miss out. David’s pick just came out, so there’s still plenty of time to get the full story on this remarkable company.
Simply click here to learn how you can unlock the full details behind this new recommendation and join Stock Advisor.
In case you’re strapped for time, I just tested it myself and joining took less than two minutes.
Please don’t delay – click here now to get started.
Access the details behind David’s newest ideas
This is your chance to get in early on of what could prove to be very special investment advice.
Think about how many investing trends you’ve missed out on, even though you knew they were going to be big.
Don’t let that happen again. This is your chance to get in early.
I urge you to take action today so you can learn the time-tested tactics savvy investors are using to systematically build their wealth. Simply enter your email address below to get started.
Hi, that’s MTCH — covered here: http://www.stockgumshoe.com/reviews/motley-fool-stock-advisor/looking-for-motley-fools-is-this-new-ipo-stock-the-next-100-bagger/